Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity

 Blogger's Note: posted today is 2nd research article regarding the specifics of  Erlotinib and ovarian cancer (Hirte/McMaster)

open access

"Erlotinib was shown to be more sensitive in the doxorubicin-resistant human breast cancer cell lines and paclitaxel-resistant human ovarian cancer cell lines [51] and the sensitivity was positively correlated with EGFR expression. More references were provided in Additional file 1,
Supplementary information Text II."